462501 Diminished Effectiveness of Neutralizing Antibodies for Respiratory Illnesses Due to Mass Transfer Limitations

Monday, November 14, 2016
Grand Ballroom B (Hilton San Francisco Union Square)
Andrea DiVenere, Chemical Engineering, University of Texas at Austin, Austin, TX and Jennifer A Maynard, Chemical Engineering, The University of Texas at Austin, Austin, TX

Respiratory illnesses, such as whopping cough, RSV, and influenza, present a two-faced challenge for the design of bio-therapeutics. Immune recognition is easily overcome by common techniques such as library screening, phage display, and single-cell phenotyping. Yet, effectively neutralizing antibodies are often ineffective in vivo. We identify this discontinuity as a result of a mass transfer limitation. The common routes of antibody introduction to the body lack the lung localization that is seen in respiratory illnesses. We show here that an anti-Bordetella pertussis antibody is over 90% effective at neutralizing immune cell invasion in vitro, but exhibits nominal protection in an in vivo murine model when injected intraperitoneally. Rather, when directly administered to the lungs by a nanoparticle-assisted aerosol route, the in vitro predicted protection is observed. While further work is investigating a more practical route for larger proteins, we propose here an essential consideration in respiratory antibody engineering design.

Extended Abstract: File Not Uploaded
See more of this Session: Poster Session: Bioengineering
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division